Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
TYK2: An emerging therapeutic target in rheumatic disease
Nat Rev Rheumatol 2024 DOI 10.1038/s41584-024-01093-w Epub ahead of print
TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases, including SLE, and could potentially have a safety profile that differs from other JAK inhibitors.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.